Oral vinorelbine (Navelbine®) is recommended for use within NHS Wales as a single agent (in line with current NICE recommendations for IV vinorelbine), for the treatment of advanced breast cancer stage III and IV relapsing after or refractory to an anthracycline-containing regimen. Oral vinorelbine (Navelbine®) should only be initiated by specialists experienced in the treatment of breast cancer. Oral vinorelbine (Navelbine®) should not presently be recommended for shared care.